APA (7th ed.) Citation

Cranmer, H., Lin, H., Kay, S., & Cazzato, S. (2022). POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex. Value in Health, 25(1), S27. https://doi.org/10.1016/j.jval.2021.11.126

Chicago Style (17th ed.) Citation

Cranmer, H., HM Lin, S. Kay, and S. Cazzato. "POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex." Value in Health 25, no. 1 (2022): S27. https://doi.org/10.1016/j.jval.2021.11.126.

MLA (9th ed.) Citation

Cranmer, H., et al. "POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex." Value in Health, vol. 25, no. 1, 2022, p. S27, https://doi.org/10.1016/j.jval.2021.11.126.